Cargando…

Variables Related to Working Capability among Swiss Patients with Multiple Sclerosis—A Cohort Study

INTRODUCTION: Reduced working capability is one of the most devastating consequences of multiple sclerosis (MS). We aimed to study working capability and related variables in Swiss MS patients. MATERIALS AND METHODS: A cross-sectional analysis of employment status and risk factors for reduced workin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Findling, Oliver, Baltisberger, Magdalena, Jung, Simon, Kamm, Christian P., Mattle, Heinrich P., Sellner, Johann
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4395101/ https://www.ncbi.nlm.nih.gov/pubmed/25867208 http://dx.doi.org/10.1371/journal.pone.0121856

Ejemplares similares

SWiss Atorvastatin and Interferon Beta-1b Trial In Multiple Sclerosis (SWABIMS) - rationale, design and methodology
por: Kamm, Christian P, et al.
Publicado: (2009)

The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options
por: Disanto, Giulio, et al.
Publicado: (2016)

Real‐life long‐term effectiveness of fingolimod in Swiss patients with relapsing‐remitting multiple sclerosis
por: Zecca, C., et al.
Publicado: (2018)

Cardiac Autonomic Dysfunction in Multiple Sclerosis: A Systematic Review of Current Knowledge and Impact of Immunotherapies
por: Findling, Oliver, et al.
Publicado: (2020)

Atorvastatin Added to Interferon Beta for Relapsing Multiple Sclerosis: 12-Month Treatment Extension of the Randomized Multicenter SWABIMS Trial
por: Kamm, Christian P., et al.
Publicado: (2014)

Behavioral Changes in Patients with Multiple Sclerosis
por: Heldner, Mirjam R., et al.
Publicado: (2017)

Humoral Immune Response after the Third SARS-CoV-2 mRNA Vaccination in CD20 Depleted People with Multiple Sclerosis
por: Achtnichts, Lutz, et al.
Publicado: (2021)

Atorvastatin added to interferon beta for relapsing multiple sclerosis: a randomized controlled trial
por: Kamm, Christian Philipp, et al.
Publicado: (2012)

Multiple sclerosis at the crossroads of scientific evidence and clinical translation
por: Sellner, Johann
Publicado: (2022)

Experiences of persons with multiple sclerosis with the Covid-19 vaccination: A cross-sectional study of the Swiss Multiple Sclerosis Registry
por: Stanikić, Mina, et al.
Publicado: (2023)

SARS-CoV-2 mRNA Vaccination in People with Multiple Sclerosis Treated with Fingolimod: Protective Humoral Immune Responses May Develop after the Preferred Third Shot
por: Achtnichts, Lutz, et al.
Publicado: (2022)

The capability set for work – correlates of sustainable employability in workers with multiple sclerosis
por: van Gorp, D. A. M., et al.
Publicado: (2018)

Multiple Sclerosis and SARS-CoV-2 Vaccination: Considerations for Immune-Depleting Therapies
por: Sellner, Johann, et al.
Publicado: (2021)

Real-world evidence for cladribine tablets in multiple sclerosis: further insights into efficacy and safety
por: Moser, Tobias, et al.
Publicado: (2022)

Diroximel Fumarate as a Novel Oral Immunomodulating Therapy for Relapsing Forms of Multiple Sclerosis: A Review on the Emerging Data
por: Hauer, Larissa, et al.
Publicado: (2022)

A R-Script for Generating Multiple Sclerosis Lesion Pattern Discrimination Plots
por: Marschallinger, Robert, et al.
Publicado: (2021)

Natalizumab extended-interval dosing in multiple sclerosis to mitigate progressive multifocal leukoencephalopathy risk: initial study evidence and real-world experience
por: Perncezky, Julian, et al.
Publicado: (2022)

Awareness of Stroke Risk after TIA in Swiss General Practitioners and Hospital Physicians
por: Streit, Sven, et al.
Publicado: (2015)

SARS-CoV-2 vaccination in multiple sclerosis: A clearer picture for the time point during CD20 depleting therapy
por: Schulte, Eva C., et al.
Publicado: (2021)

Correlation of disability with quality of life in patients with multiple sclerosis treated with natalizumab: primary results and post hoc analysis of the TYSabri ImPROvement study (PROTYS)
por: Achtnichts, Lutz, et al.
Publicado: (2023)

A global view of comorbidity in multiple sclerosis: a systematic review with a focus on regional differences, methodology, and clinical implications
por: Hauer, Larissa, et al.
Publicado: (2020)

Geostatistical Analysis of White Matter Lesions in Multiple Sclerosis Identifies Gender Differences in Lesion Evolution
por: Marschallinger, Robert, et al.
Publicado: (2018)

An overview of pivotal trials and real-world evidence for CD20-depleting therapy in multiple sclerosis: Immunotherapy with rituximab, ocrelizumab, and ofatumumab
por: Ovchinnikov, Arkady, et al.
Publicado: (2022)

Vitamin D Supplementation in Multiple Sclerosis: A Critical Analysis of Potentials and Threats
por: Feige, Julia, et al.
Publicado: (2020)

Reference videos reduce variability of motor dysfunction assessments in multiple sclerosis
por: D’Souza, Marcus, et al.
Publicado: (2018)

T cells as the hoped-for savior for SARS-CoV-2 vaccination during CD20-depleting antibody therapy?: Commentary for: “Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy.”
por: Bsteh, Gabriel, et al.
Publicado: (2021)

Role of Family Planning in Women With Multiple Sclerosis in Switzerland: Results of the Women With Multiple Sclerosis Patient Survey
por: Kamm, Christian P., et al.
Publicado: (2018)

Gait Variability and Multiple Sclerosis
por: Socie, Michael J., et al.
Publicado: (2013)

Long-term evaluation of NEDA-3 status in relapsing-remitting multiple sclerosis patients after switching from natalizumab to fingolimod
por: Diem, Lara, et al.
Publicado: (2018)

Balance Changes in Patients With Relapsing-Remitting Multiple Sclerosis: A Pilot Study Comparing the Dynamics of the Relapse and Remitting Phases
por: Findling, Oliver, et al.
Publicado: (2018)

Critical Illness in Patients with Multiple Sclerosis: A Matched Case-Control Study
por: Karamyan, Anush, et al.
Publicado: (2016)

Cladribine Alters Immune Cell Surface Molecules for Adhesion and Costimulation: Further Insights to the Mode of Action in Multiple Sclerosis
por: Moser, Tobias, et al.
Publicado: (2021)

Therapeutic Plasma Exchange in Multiple Sclerosis and Autoimmune Encephalitis: A Comparative Study of Indication, Efficacy, and Safety
por: Moser, Tobias, et al.
Publicado: (2019)

Adaptive Immune Responses in a Multiple Sclerosis Patient with Acute Varicella-Zoster Virus Reactivation during Treatment with Fingolimod
por: Harrer, Andrea, et al.
Publicado: (2015)

Factors associated with employment and expected work retention among persons with multiple sclerosis: findings of a cross-sectional citizen science study
por: Lehmann, Anja I., et al.
Publicado: (2020)

Determinants of early working impairments in multiple sclerosis
por: Moccia, Marcello, et al.
Publicado: (2022)

Al Qaeda suspect worked at Swiss nuclear lab
Publicado: (2009)

Al Qaeda suspect worked at Swiss nuclear lab
Publicado: (2009)

Al Qaeda suspect worked at Swiss nuclear lab
Publicado: (2009)

Al Qaeda suspect worked at Swiss nuclear lab
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_qbv4ak0qm9tkj0ntq1usdieeme